AVIEW Chest CT AI

Coreline Soft is a Korean medical imaging AI company founded in Seoul in September 2012 and listed on KOSDAQ in 2023, with subsidiaries in Germany and the United States. It focuses on CT-based AI for lung cancer screening and chronic chest and cardiovascular disease, and has operated Korea's national lung cancer screening AI for nine consecutive years.

The AVIEW software line covers thoracic analysis (LCS and LCS Plus for lung nodule detection and tracking, COPD, lung texture, interstitial lung abnormality, pulmonary embolism), cardiovascular analysis (coronary artery calcium, aortic dissection and aortic metrics), brain (NeuroCAD for intracranial hemorrhage, cerebrovascular extraction), spine and radiotherapy organ segmentation. One chest CT can yield both lung and coronary calcium results. Customers are hospitals, screening programmes and teleradiology networks.

• Lung cancer screening: AVIEW LCS and LCS Plus detect, measure and track lung nodules on CT.
• Chronic lung analysis: quantitative emphysema, airway, lung texture and interstitial lung abnormality analysis.
• Cardiovascular AI: coronary artery calcium scoring plus aortic dissection and diameter analysis.
• Emergency findings: pulmonary embolism detection and NeuroCAD for intracranial hemorrhage triage.
• Spine and bone: spinal canal stenosis and vertebral bone density analysis.
• Research tools: radiotherapy organ segmentation and 3D modeling for printing.

Oncology and lung hospitals in Vietnam could run low-dose CT lung cancer screening with automated nodule tracking. Private check-up centers could report coronary calcium and emphysema from the same chest CT in premium packages. Emergency departments could prioritize CT scans with suspected hemorrhage or pulmonary embolism.

Turns a single low-dose chest CT into lung nodule, emphysema and coronary calcium results, adding value to each screening exam. Tracks nodules over time to support follow-up decisions in lung cancer screening. Detects urgent findings such as pulmonary embolism, aortic dissection and intracranial hemorrhage for prioritization. Carries approvals from FDA, CE MDR, PMDA, TGA and Singapore HSA, easing adoption in multiple markets.

Low-dose CT lung cancer screening is expanding in Asia and Europe, and lung cancer is among the most common cancers in Vietnam. Screening programmes increasingly expect one scan to also report coronary calcium and emphysema, and regional approvals such as Singapore's HSA help Korean imaging AI move into Southeast Asian hospitals.

Coreline Soft was founded in September 2012 in Seoul and listed on KOSDAQ in September 2023, with Coreline Europe GmbH in Oberursel, Germany and Coreline North America in Georgia, US. Approvals include FDA, MFDS, PMDA, TGA, Health Canada, ANVISA and Singapore HSA, plus CE MDR and UKCA. It holds ISO/IEC 42001, ISO/IEC 27001 and MDSAP. Partners include Canon Medical, INFINITT North America and Doctor Net Japan.